[Nguyen]

Hello Sassy,

Many thanks for responding.

I am looking for data to let us decide on a few ideas:

1_ Is threre any new endocrine agent?
2_ Her next treatment will be either Herceptin-DM1 or Lapatinib+Capecitabine. Are there any new data to aid in select of one over the other as the next step from the current treatment (Herceptin+Lapatinib+Femara+Zometa)
3_ Do we keep Femara in the "next" treatment
4_ There're data indicating change in hormone and/or her2 receptors status from primary to distant mestastatic tumours for a small percentage of patients. Is there any data indicating in changes in these receptors status for mestastatic tumours after being treated for so "long".

Usually, after abstracts of each conference are available, I read through all of them to ferret out answers (hint of answers) to questions that I have. This is quite a bit time consuming, so it's o.k if you can't.

Thanks so much